韩梦婷,沈继伟,吴英良
HAN Mengting,SHEN Jiwei,WU Yingliang

• 1:沈阳药科大学生命科学与生物制药学院

摘要(Abstract)：

目的综述ALK/ROS1抑制剂治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的最新研究进展。方法通过查阅文献,对治疗晚期NSCLC患者的ALK/ROS1抑制剂进行总结。结果克唑替尼被报道在NSCLC病人中抑制间变性淋巴瘤激酶(ALK)和ROS1重排高度有效和耐受性良好,但在初始治疗后的9~12个月出现了耐药问题,随后又有一些新的ALK抑制剂被研发出来。结论耐药基因的发现及新ALK/ROS1抑制剂的研发具有重要意义和广阔前景。
Objective Toreview the latest research progress of ALK/ROS1 inhibitors in the treatment of advanced non-small cell lung cancer( NSCLC). Methods By review ing the literature,w e summarize the ALK/ROS1 inhibitors in the treatment of advanced NSCLC. Results Crizotinib w as reported to be highly effective and w ell tolerated in inhibiting the alteration of anaplastic lymphoma kinase( ALK) and ROS1 in NSCLC patients,How ever,resistance to crizotinib emerges after treatment for 9 to 12 months,follow ed by several new ALK inhibitors have been developed. Conclusion The discovery of drug-resistant genes and the development of new ALK/ROS1 inhibitors have great significance and broad prospects.

关键词(KeyWords)： EML4-ALK;ROS1;克唑替尼;非小细胞肺癌
EML4-ALK;ROS1;crizotinib;non-small cell lung cancer

Abstract:

Keywords:

基金项目(Foundation): 沈阳药科大学中青年骨干人才培养计划资助项目(ZQN2015003)

作者(Author): 韩梦婷,沈继伟,吴英良
HAN Mengting,SHEN Jiwei,WU Yingliang

DOI: 10.14066/j.cnki.cn21-1349/r.2018.01.014

参考文献(References)：

• [1]SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2016[J].A Cancer Journal for Clinicians,2016,66:7-30.
• [2]ETTINGER D,AKERLEY W,BORGHAEI H,et al.Non-small cell lung cancer[J].Journal of the National Comprehensive Cancer Network,2012,10:1236-1271.
• [3]SODA M,CHOR Y L,ENOMOTO M,et al.Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer[J].Nature,2007,448(7153):561-566.
• [4]SHAW A T,YEAP B Y,MINO-KENUDSON M,et al.Clinical features and outcome of patients with nonsmall-cell lung cancer who harbor EML4-ALK[J].Journal of Clinical Oncology,2009,27:4247-4253.
• [5]VIJAYVERGIA N,MEHRA R.Clinical challenges in targeting anaplastic lymphoma kinase in advanced nonsmall cell lung cancer[J].Cancer Chemotherapy and Pharmacology,2014,74(3):437-446.
• [6]GANIOR J F,SHAW A T.Novel targets in non-small cell lung cancer:ROS1 and RET fusions[J].Oncologist,2013,18(7):865-875.
• [7]RIKOVA K,GUO A,ZENG Q,et al.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer[J].Cell,2007,131:1190-1203.
• [8]WARTH A,MULEY T,DIENEMANN H,et al.ROS1expression and translocations in non-small-cell lung cancer:clinicopathological analysis of 1478 cases[J].Histopathology 2014,65:187-194.
• [9]SHOLL L M,SUN H,BUTANEY M,et al.ROS1 immunohistochemistry for detection of ROS-rearranged lung adenocarcinomas[J].American Journal of Surgical Pathology,2013,37(9):1441-1449.
• [10]CHIN L P,SOO R A,SOONG R,et al.Targeting ROS1with analastic lymphoma kinase inhibitors:a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer[J].Journal of Thoracic Oncology,2012,7(11):1625-1630.
• [11]CAMIDGE D R,BANG Y J,KWAK E L,et al.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer:updated results from a phase 1 study[J].Lancet Oncology,2012,13:1011-1019.
• [12]SHAW A T,KIM D W,NAKAGAWA K,et al.Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J].The New England Journal of Medicine,2013,368:2385-2394.
• [13]GRIDELLI C,PETERS S,SGAMBATO A,et al.ALK inhibitors in the treatment of advanced NSCLC[J].Cancer Treatment Reviews,2014,40:300-306.
• [14]BERGETHON K,SHAW A T,OU S H,et al.ROS1 rearrangements define a unique molecular class of lung cancers[J].Journal of Clinical Oncology,2012,30:863-870.
• [15]SHAW A T,OU S H,BANG Y J,et al.Crizotinib in ROS1-rearranged non-small-cell lung cancer[J].The New England Journal of Medicine,2014,371:1963-1971.
• [16]CHOI Y L,SODA M,YAMASHITA Y,et al.EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors[J].The New England Journal of Medicine,2010,363:1734-1739.
• [17]QI X,MA W,LI S,et al.Overcoming crizotinib resistance in ALK-rearranged non-small cell lung cancer[J].Lung Cancer,2014,85:335-336.
• [18]DOEBELE R C,PILLING A B,AISNER D L,et al.Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer[J].Clinical Cancer Research,2012,18(5):1472-1482.
• [19]SASAKI T,KOIVUNEN J,OGINO A,et al.A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors[J].Clinical Cancer Research,2011,71(18):6051-6060.
• [20]SUN H,LI Y,TIAN S,et al.P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1tyrosine kinase:clues from free energy landscape[J].Plos Computational Biology,2014,10(7):e1003729.
• [21]KANAAN Z,KLOECKER G H,PAINTAL A,et al.Novel targeted therapies for resistant ALK-rearranged nonsmall-cell lung cancer:ceritinib and beyond[J].Onco Targets and Therapy,2015,8:885-892.
• [22]FRIBOULET L,Li N,KATAYAMA R,et al.The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer[J].Cancer Discovery,2014,4:662-673.
• [23]KHOZIN S,BLUMENTHAL G M,ZHANG L,et al.FDA approval:ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer[J].Clinical Cancer Research,2015,21:2436-2439.
• [24]YONESHIMA Y,OKAMOTO I,TAKANO T,et al.Successful treatment with alectinib-induced esophageal ulceration[J].Lung Cancer,2015,88(3):349-351.
• [25]GRIDELLI C,PETERS S,SGAMBATO A,et al.ALK inhibitors in the treatment of advanced NSCLC[J].Cancer Treat Reviews,2014,40:300-306.